Divi’s Laboratories Limited, headquartered in Hyderabad, is a prominent global Indian pharmaceutical company specializing in the production of intermediates and active pharmaceutical ingredients (APIs). Established with a focus on providing high-quality pharmaceutical products, the company has earned a reputation for its excellence in manufacturing generic APIs and intermediates, which are synthesized based on market demand.
One of the key strengths of Divi’s Laboratories lies in its ability to produce APIs and intermediates tailored to specific requirements. This customer-centric approach allows the company to respond effectively to the diverse needs of pharmaceutical companies worldwide, ensuring a steady demand for its products.
In addition to its core pharmaceutical business, Divi’s Laboratories has diversified its operations through its subsidiary, Divi’s Nutraceuticals. This subsidiary focuses on the production and distribution of ingredients for nutraceuticals, which are products derived from food sources with extra health benefits. Nutraceuticals have gained popularity for their potential to promote health and prevent various diseases, making this subsidiary a strategic move to tap into the growing health and wellness market.
With its commitment to quality and innovation, Divi’s Laboratories has secured a significant position in the pharmaceutical industry. The company’s products play a vital role in the healthcare sector by serving as essential components in the manufacturing of various pharmaceutical formulations.
Notably, Divi’s Laboratories has achieved substantial financial success, as reflected in its market capitalization. As the fourth-largest publicly traded pharmaceutical firm in India by market capitalization, the company’s strong performance underscores its position as a leader in the industry. This financial stability not only showcases its robust business model but also instills confidence among investors and stakeholders.
Overall, Divi’s Laboratories Limited stands as a reputable and influential player in the global pharmaceutical arena, renowned for its production of high-quality APIs, intermediates, and nutraceutical ingredients. Through its dedication to innovation, customer satisfaction, and adherence to stringent quality standards, the company continues to make significant contributions to the pharmaceutical and healthcare sectors, both in India and internationally.
| Website | divislabs.com |
| Industry | Pharmaceutical |
| Company size | 16,500+ [2022] |
| Headquarters | Divi towers Hyderabad Telangana, India |
| Founded | 12 October 1990 |
| Specialties | Active pharmaceutical ingredients nutraceuticals |
| Founder | Divi satchandra kiran |
| Award | ESH 2022 excellence award by CII south region |
| CEO | Dr. Kiran S. Divi |
Average Salary Package
Senior Managers at Divis Laboratories receive an annual compensation of Rs. 17.1 lakhs, making them the highest paid employees. The top 10% of employees make over 4.58 lakhs rupees annually, and the top 1% make over 13 lakhs.
Here are some additional Divis Laboratories salaries:
1. Fresher: Rs. 1,95,625 per year
2. Research Associate in Chemical Research: Rs. 2,37,428 per year
3. Engineer/Safety Officer: Rs. 3,28,428 per year
4. Industrial Engineer: Rs. 2,53,666 year
5. Pharmaceuticals: Rs. 2,10,833/year for a research analyst
6. Additional Biotechnology/Pharmaceutical/Research & Development: Rs. 2,31,000/yr
7. Research Scientist: Rs. 4,58,200 year
8. For experience ranging from 1 to 5 years, the average pay for a production chemist at Divis Laboratories India is 3.2 Lakhs. The remuneration is between 1.6 and 5.6 lakhs rupees.
History
As the Divi’s Research Centre, Divi’s Laboratories was founded in 1990. For the production of APIs and intermediates, the business originally began developing commercial manufacturing procedures. In order to advertise its intention to join the manufacturing of API and intermediates, Divi’s Research Centre changed its name to Divi’s Laboratories Limited in 1994.In 1995, the company opened its first manufacturing facility in Choutuppal, Telangana, as a result. The second production site of the business opened its doors in 2002 in Chippada, not far from Visakhapatnam.
On February 17, 2003, the company made its first public offering (IPO), becoming publicly traded. A research centre was opened by the business in Hyderabad in 2010.
Divi’s is a Public limited company listed on the Indian stock exchange with a revenue of ~$1.2B for the year 2021-22.
Product
| Therapeutic category | Product |
| Anti-Parkinson | Benserazide |
| Anti epilepsy | Brivaracetam |
| Anti-Coagulant | Rivaroxaban |
| Anti-Viral | Nirmatrelvir |
| Anti Hypertension | Losartan |
| Overactive bladder | Mirabegron |
| Antidiabetic | Vildagliptin |
| Anti- Coagulant | Dabigatran |
| Anticoagulants | Apixaban |
| Contrast Medium | Gadoterate Meglumine |
| Contrast Medium | Gadopentetate Dimeglumine |
| Contrast Medium | Iodixanol |
| Anti- Coagulant | Vildagliptin |
| Contrast Medium | Iobitridol |
| Contrast Medium | Ioversol |
